DragonQueenEatsDips
voted
Happy Friday, mooers! Welcome back to Weekly Buzz, where we review the news, performance, and community sentiment of the selected buzzing stocks on moomoo platform based on search and message volumes of this week! Answer the Weekly Topic question for a chance to win an award next week!
Make Your Choice
Weekly Buzz
The week ended with a 4.8 magnitude earthquake that rattled the Jersey City moomoo office, and the financial district of New York shook right outside t...
Make Your Choice
Weekly Buzz
The week ended with a 4.8 magnitude earthquake that rattled the Jersey City moomoo office, and the financial district of New York shook right outside t...
+9
49
13
DragonQueenEatsDips
liked
$Tesla (TSLA.US)$ will become an interstellar power company starting with providing electricity to moon bases with its equipment ferried by spacex .. hold on to Yr stocks -)
4
DragonQueenEatsDips
liked
$Tesla(TSLA.US$
1000% profit and keep increasing!
1000% profit and keep increasing!
5
1
DragonQueenEatsDips
liked
As this round of interest rate hikes comes to an end, the United States has reached a crossroads again. Should it fall into the great stagflation similar to those after 1973, or continue the information revolution as it did after 1995, with its opponents falling into recession one by one? Crude oil has once again become an important influencing factor. By comparing historical experiences, it can be found that the risk of ...
41
4
DragonQueenEatsDips
reacted to
$Tesla(TSLA.US$
fly to the moons 200 soon🤩
fly to the moons 200 soon🤩
5
DragonQueenEatsDips
liked
$Kintara Therapeutics(KTRA.US$ Kintara Therapeutics Expands REM-001 Clinical Study To Include Patients On Pembrolizumab
3
DragonQueenEatsDips
liked
$Kintara Therapeutics(KTRA.US$ Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab PRNewswire 27-Mar-2024 9:00 AM SAN DIEGO, March 27, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the expansion of the inclusion criteria in the open label 15- patient REM-001 study in cutaneous metastatic ...
3